Larimar Therapeutics Inc
$ 3.68
6.05%
04 Dec - close price
- Market Cap 296,999,000 USD
- Current Price $ 3.68
- High / Low $ 3.75 / 3.36
- Stock P/E N/A
- Book Value 1.62
- EPS -1.96
- Next Earning Report 2026-03-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.43 %
- ROE -0.78 %
- 52 Week High 6.91
- 52 Week Low 1.61
About
Larimar Therapeutics, Inc. is a clinical-stage biotechnology firm located in Bala Cynwyd, Pennsylvania, dedicated to developing groundbreaking therapies for rare diseases with significant unmet medical needs. The company utilizes advanced technologies and leverages extensive scientific expertise to enhance patient outcomes through its robust drug pipeline. Positioned for leadership in the rare disease market, Larimar is actively fostering strategic partnerships that aim to create substantial value for stakeholders while tackling critical health challenges.
Analyst Target Price
$16.70
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-05 | 2025-05-07 | 2025-03-12 | 2024-10-30 | 2024-08-07 | 2024-05-09 | 2024-03-14 | 2023-11-14 | 2023-08-10 | 2023-05-15 | 2023-03-14 |
| Reported EPS | -0.61 | -0.41 | -0.46 | -0.45 | -0.24 | -0.34 | -0.27 | -0.3 | -0.21 | -0.19 | -0.15 | -0.21 |
| Estimated EPS | -0.4128 | -0.4803 | -0.4091 | -0.3194 | -0.37 | -0.31 | -0.23 | -0.25 | -0.22 | -0.19 | -0.25 | -0.37 |
| Surprise | -0.1972 | 0.0703 | -0.0509 | -0.1306 | 0.13 | -0.03 | -0.04 | -0.05 | 0.01 | 0 | 0.1 | 0.16 |
| Surprise Percentage | -47.7713% | 14.6367% | -12.4419% | -40.8892% | 35.1351% | -9.6774% | -17.3913% | -20% | 4.5455% | 0% | 40% | 43.2432% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-18 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.4142 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LRMR
2025-11-02 10:39:49
|Larimar Therapeutics announced positive long-term data from its open-label study of nomlabofusp for Friedreich’s Ataxia, showing increased skin FXN levels and consistent directional improvement across key clinical outcomes. The company also provided updates on its development program, including a modified starting dose regimen due to anaphylaxis events and a targeted BLA submission in Q2 2026. These results suggest nomlabofusp has the potential to be a disease-modifying therapy for FA.
2025-11-02 10:39:49
The Rosen Law Firm has initiated an investigation into potential securities claims on behalf of investors in Larimar Therapeutics, Inc. (NASDAQ: LRMR) due to allegations of materially misleading business information. This investigation follows a significant stock drop after seven anaphylaxis events were disclosed in a study for Friedreich’s ataxia. Investors who purchased Larimar Therapeutics securities may be entitled to compensation through a class action lawsuit.
2025-10-16 09:32:59
The article announces an opportunity for investors in Larimar Therapeutics, Inc. (LRMR) to join a fraud investigation led by The Schall Law Firm. This investigation is being initiated on behalf of investors who have experienced losses with their investments in the company.
2025-10-16 08:45:08
DJS Law Group is investigating Larimar Therapeutics, Inc. (NASDAQ: LRMR) for potential securities fraud violations. The investigation stems from a significant drop in Larimar's share price following the announcement of an open-label study showing severe allergic reactions to its Friedreich's Ataxia treatment, despite the company portraying the results as positive. Shareholders who suffered losses are encouraged to contact DJS Law Group to discuss their rights.
2025-10-16 01:31:04
The DJS Law Group is investigating Larimar Therapeutics, Inc. (NASDAQ: LRMR) for potential securities law violations after its stock fell significantly. The investigation follows a study of its Friedreich's Ataxia treatment, Nomlabofusp, where multiple participants experienced severe allergic reactions, despite the company's portrayal of positive results. The law group is seeking shareholders who suffered losses to participate in the investigation.
2025-10-16 01:09:00
The Schall Law Firm has initiated a fraud investigation into Larimar Therapeutics, Inc. (LRMR) following a significant stock drop. This comes after the company announced "positive" data from a study for Friedreich's Ataxia, but also disclosed severe allergic reactions in seven participants, causing its shares to fall over 33.6%. The firm is encouraging investors who suffered losses to contact them to discuss their legal rights.
